Thomas Michaeli

783 total citations
39 papers, 467 citations indexed

About

Thomas Michaeli is a scholar working on Economics and Econometrics, Surgery and General Health Professions. According to data from OpenAlex, Thomas Michaeli has authored 39 papers receiving a total of 467 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Economics and Econometrics, 7 papers in Surgery and 6 papers in General Health Professions. Recurrent topics in Thomas Michaeli's work include Health Systems, Economic Evaluations, Quality of Life (21 papers), Pharmaceutical Economics and Policy (14 papers) and Economic and Financial Impacts of Cancer (13 papers). Thomas Michaeli is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (21 papers), Pharmaceutical Economics and Policy (14 papers) and Economic and Financial Impacts of Cancer (13 papers). Thomas Michaeli collaborates with scholars based in Germany, United Kingdom and United States. Thomas Michaeli's co-authors include Daniel Tobias Michaeli, Julia Caroline Michaeli, Tobias Boch, Sebastian Albers, Hendrik Jürges, Panos Kanavos, D. R. Absolom, Carel J. van Oss, Mónica Maldonado and Rachel Würstlein and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Scientific Reports.

In The Last Decade

Thomas Michaeli

38 papers receiving 454 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Michaeli Germany	13	240	79	55	51	48	39	467
Daniel Tobias Michaeli Germany	14	291 1.2×	80 1.0×	57 1.0×	61 1.2×	48 1.0×	48	550
Prasun Subedi United States	10	142 0.6×	31 0.4×	80 1.5×	27 0.5×	97 2.0×	22	434
Anthony Louder United States	11	72 0.3×	38 0.5×	56 1.0×	26 0.5×	32 0.7×	17	353
Ashlyn Pinto Canada	5	262 1.1×	14 0.2×	95 1.7×	30 0.6×	34 0.7×	10	430
Joanna P. MacEwan United States	12	118 0.5×	22 0.3×	59 1.1×	38 0.7×	37 0.8×	53	391
Zhimin Yang China	11	74 0.3×	31 0.4×	129 2.3×	51 1.0×	86 1.8×	25	397
Karen V. MacDonald Canada	12	95 0.4×	67 0.8×	20 0.4×	51 1.0×	30 0.6×	36	364
Scott Gavura Canada	11	170 0.7×	27 0.3×	252 4.6×	40 0.8×	88 1.8×	43	512
G. Caleb Alexander United States	8	169 0.7×	14 0.2×	28 0.5×	54 1.1×	18 0.4×	11	391
Gabriel Tremblay United States	12	56 0.2×	40 0.5×	107 1.9×	48 0.9×	74 1.5×	84	425

Countries citing papers authored by Thomas Michaeli

Since Specialization

Citations

This map shows the geographic impact of Thomas Michaeli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Michaeli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Michaeli more than expected).

Fields of papers citing papers by Thomas Michaeli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Michaeli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Michaeli. The network helps show where Thomas Michaeli may publish in the future.

Co-authorship network of co-authors of Thomas Michaeli

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Michaeli. A scholar is included among the top collaborators of Thomas Michaeli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Michaeli. Thomas Michaeli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Michaeli, Daniel Tobias, Thomas Michaeli, Sebastian Albers, & Julia Caroline Michaeli. (2024). Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs. Targeted Oncology. 19(5). 797–809. 3 indexed citations

Michaeli, Julia Caroline, Thomas Michaeli, Dario Trapani, et al.. (2024). Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price. Breast Cancer. 31(6). 1144–1155. 2 indexed citations

Michaeli, Daniel Tobias, Thomas Michaeli, Sebastian Albers, & Julia Caroline Michaeli. (2024). Clinical trial design and treatment effects: a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications. BMJ evidence-based medicine. 29(5). 333–341. 5 indexed citations

Michaeli, Daniel Tobias & Thomas Michaeli. (2024). Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price. Journal of the National Comprehensive Cancer Network. 22(4). 7 indexed citations

Michaeli, Thomas & Daniel Tobias Michaeli. (2024). Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending. Value in Health. 27(4). 449–457. 5 indexed citations

Michaeli, Daniel Tobias, Julia Caroline Michaeli, Sebastian Albers, Tobias Boch, & Thomas Michaeli. (2023). Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. American Journal of Cardiovascular Drugs. 23(5). 477–495. 52 indexed citations

Michaeli, Daniel Tobias, Thomas Michaeli, Sebastian Albers, Tobias Boch, & Julia Caroline Michaeli. (2023). Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. The European Journal of Health Economics. 25(6). 979–997. 53 indexed citations

Michaeli, Daniel Tobias & Thomas Michaeli. (2023). Spending on Orphan Cancer Drugs for Ultra-Rare, Rare, and Common Diseases. SSRN Electronic Journal. 7 indexed citations

Michaeli, Thomas, Hendrik Jürges, & Daniel Tobias Michaeli. (2023). FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis. BMJ. 381. e073242–e073242. 28 indexed citations

10.

Michaeli, Daniel Tobias & Thomas Michaeli. (2023). Partial Orphan Cancer Drugs: FDA Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending. SSRN Electronic Journal. 2 indexed citations

11.

Michaeli, Daniel Tobias & Thomas Michaeli. (2023). Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology. Value in Health. 26(11). 1590–1600. 20 indexed citations

12.

Michaeli, Julia Caroline, Daniel Tobias Michaeli, Tobias Boch, Sebastian Albers, & Thomas Michaeli. (2022). Socio‐economic burden of disease: Survivorship costs for renal cell carcinoma. European Journal of Cancer Care. 31(3). e13569–e13569. 2 indexed citations

13.

Michaeli, Daniel Tobias, Julia Caroline Michaeli, Tobias Boch, & Thomas Michaeli. (2022). Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany. Cardiovascular Drugs and Therapy. 37(4). 683–694. 16 indexed citations

14.

Michaeli, Daniel Tobias, et al.. (2022). Medical education and mental health during COVID-19: a survey across 9 countries. International Journal of Medical Education. 13. 35–46. 23 indexed citations

15.

Michaeli, Daniel Tobias, et al.. (2022). Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors. Therapeutic Innovation & Regulatory Science. 56(2). 313–322. 18 indexed citations

16.

Michaeli, Daniel Tobias, et al.. (2022). Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa. Clinical Drug Investigation. 42(4). 333–343. 10 indexed citations

17.

Michaeli, Daniel Tobias, Julia Caroline Michaeli, Tobias Boch, & Thomas Michaeli. (2022). Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy. Clinical Drug Investigation. 42(8). 643–656. 13 indexed citations

18.

Michaeli, Daniel Tobias, et al.. (2022). 874P The economic burden of surviving malignant melanoma. Annals of Oncology. 33. S948–S949. 1 indexed citations

19.

Michaeli, Thomas & Daniel Tobias Michaeli. (2021). Prostate cancer follow-up costs in Germany from 2000 to 2015. Journal of Cancer Survivorship. 16(1). 86–94. 6 indexed citations

20.

Michaeli, Thomas, Julia Caroline Michaeli, & Daniel Tobias Michaeli. (2021). Testicular cancer follow-up costs in Germany from 2000 to 2015. Journal of Cancer Research and Clinical Oncology. 147(8). 2249–2258. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact